{"id":55526,"date":"2023-04-05T10:03:29","date_gmt":"2023-04-05T08:03:29","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/avacta-announces-first-patient-dosed-in-fifth-cohort-of-ava6000-phase-ia-dose-escalation-study\/"},"modified":"2023-04-05T10:03:29","modified_gmt":"2023-04-05T08:03:29","slug":"avacta-announces-first-patient-dosed-in-fifth-cohort-of-ava6000-phase-ia-dose-escalation-study","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/avacta-announces-first-patient-dosed-in-fifth-cohort-of-ava6000-phase-ia-dose-escalation-study\/","title":{"rendered":"Avacta Announces First Patient Dosed in Fifth Cohort of AVA6000 Phase Ia Dose Escalation Study"},"content":{"rendered":"<div>\n<p>LONDON &amp; WETHERBY, England&#8211;(BUSINESS WIRE)&#8211;Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, announces that the first patient has been dosed in the fifth cohort of the first-in-human phase I trial (ALS-6000-101) of AVA6000. This follows the approval of an amended clinical trial protocol by the Medical and Healthcare Products Regulatory Agency (MHRA) to allow for higher levels of dosing.<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20230405005422\/en\/1756840\/5\/Avacta_%28RGB%29_reg.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230405005422\/en\/1756840\/21\/Avacta_%28RGB%29_reg.jpg\"><\/a><\/p>\n<p>\nAvacta\u2019s Safety Data Monitoring Committee (SDMC), comprised of clinicians currently recruiting patients, has recommended that the phase Ia dose escalation clinical trial continues to a fifth dose cohort at 250mg\/m<sup>2<\/sup>, following the favourable safety profile of AVA6000 generated in the study to date. Escalation to this level of dosing falls outside of the original clinical trial protocol, and therefore the protocol required amendment and approval by the MHRA, which has now been completed. This continued dose escalation is aimed at identifying a maximum tolerated dose (MTD) necessary to inform the dosing levels for the phase 1b and future studies.<\/p>\n<p>\n<b>Dr Alastair Smith, Chief Executive Officer of Avacta Group, commented: <\/b><i>\u201cWe are very much encouraged by the positive safety and tolerability data emerging from the dose escalation phase 1a study of AVA6000. Following the recommendation from the SDMC, and approval by the MHRA, we are pleased to commence dosing in the fifth patient cohort of this trial. The recent confirmation of release of active chemotherapy in the tumour tissue and the safety data being generated in the ALS-6000-101 study are providing detailed insights into the pre|CISION\u2122 platform which add significant value to the technology and confirm the tumour targeting potential of the pre|CISION\u2122 platform.\u201d<\/i><\/p>\n<p>\nThis announcement has been approved for release by Alastair Smith, Chief Executive Officer of Avacta Group plc.<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>Media Contact:<\/b><br \/>Lily Jeffery, Zyme Communications<br \/>\n<br \/>T: +44 (0)7891 477 378<br \/>\n<br \/>E: <a target=\"_blank\" href=\"&#x6d;&#x61;&#x69;&#x6c;&#x74;&#x6f;&#x3a;&#x6c;&#x69;&#x6c;&#x79;&#46;&#106;&#101;&#102;&#102;&#101;&#114;y&#64;zyme&#x63;&#x6f;&#x6d;&#x6d;&#x75;&#x6e;&#x69;&#x63;&#x61;&#x74;&#x69;&#x6f;&#110;&#115;&#46;&#99;&#111;&#109;\" rel=\"nofollow noopener\" shape=\"rect\">&#x6c;&#x69;&#x6c;&#x79;&#x2e;&#x6a;&#x65;&#x66;&#x66;&#x65;&#x72;&#x79;&#x40;&#x7a;&#x79;&#x6d;&#x65;&#x63;&#x6f;&#x6d;&#x6d;&#x75;&#x6e;&#x69;&#x63;&#x61;&#x74;&#x69;&#x6f;&#x6e;&#x73;&#x2e;&#x63;&#x6f;&#x6d;<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>LONDON &amp; WETHERBY, England&#8211;(BUSINESS WIRE)&#8211;Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, announces that the first patient has been dosed in the fifth cohort of the first-in-human phase I trial (ALS-6000-101) of AVA6000. This follows the approval of an amended clinical trial protocol by the Medical &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/avacta-announces-first-patient-dosed-in-fifth-cohort-of-ava6000-phase-ia-dose-escalation-study\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-55526","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Avacta Announces First Patient Dosed in Fifth Cohort of AVA6000 Phase Ia Dose Escalation Study - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/avacta-announces-first-patient-dosed-in-fifth-cohort-of-ava6000-phase-ia-dose-escalation-study\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Avacta Announces First Patient Dosed in Fifth Cohort of AVA6000 Phase Ia Dose Escalation Study - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"LONDON &amp; WETHERBY, England&#8211;(BUSINESS WIRE)&#8211;Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, announces that the first patient has been dosed in the fifth cohort of the first-in-human phase I trial (ALS-6000-101) of AVA6000. This follows the approval of an amended clinical trial protocol by the Medical ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/avacta-announces-first-patient-dosed-in-fifth-cohort-of-ava6000-phase-ia-dose-escalation-study\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-05T08:03:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230405005422\/en\/1756840\/21\/Avacta_%28RGB%29_reg.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avacta-announces-first-patient-dosed-in-fifth-cohort-of-ava6000-phase-ia-dose-escalation-study\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avacta-announces-first-patient-dosed-in-fifth-cohort-of-ava6000-phase-ia-dose-escalation-study\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Avacta Announces First Patient Dosed in Fifth Cohort of AVA6000 Phase Ia Dose Escalation Study\",\"datePublished\":\"2023-04-05T08:03:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avacta-announces-first-patient-dosed-in-fifth-cohort-of-ava6000-phase-ia-dose-escalation-study\\\/\"},\"wordCount\":324,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avacta-announces-first-patient-dosed-in-fifth-cohort-of-ava6000-phase-ia-dose-escalation-study\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230405005422\\\/en\\\/1756840\\\/21\\\/Avacta_%28RGB%29_reg.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avacta-announces-first-patient-dosed-in-fifth-cohort-of-ava6000-phase-ia-dose-escalation-study\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avacta-announces-first-patient-dosed-in-fifth-cohort-of-ava6000-phase-ia-dose-escalation-study\\\/\",\"name\":\"Avacta Announces First Patient Dosed in Fifth Cohort of AVA6000 Phase Ia Dose Escalation Study - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avacta-announces-first-patient-dosed-in-fifth-cohort-of-ava6000-phase-ia-dose-escalation-study\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avacta-announces-first-patient-dosed-in-fifth-cohort-of-ava6000-phase-ia-dose-escalation-study\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230405005422\\\/en\\\/1756840\\\/21\\\/Avacta_%28RGB%29_reg.jpg\",\"datePublished\":\"2023-04-05T08:03:29+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avacta-announces-first-patient-dosed-in-fifth-cohort-of-ava6000-phase-ia-dose-escalation-study\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avacta-announces-first-patient-dosed-in-fifth-cohort-of-ava6000-phase-ia-dose-escalation-study\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avacta-announces-first-patient-dosed-in-fifth-cohort-of-ava6000-phase-ia-dose-escalation-study\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230405005422\\\/en\\\/1756840\\\/21\\\/Avacta_%28RGB%29_reg.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230405005422\\\/en\\\/1756840\\\/21\\\/Avacta_%28RGB%29_reg.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avacta-announces-first-patient-dosed-in-fifth-cohort-of-ava6000-phase-ia-dose-escalation-study\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Avacta Announces First Patient Dosed in Fifth Cohort of AVA6000 Phase Ia Dose Escalation Study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Avacta Announces First Patient Dosed in Fifth Cohort of AVA6000 Phase Ia Dose Escalation Study - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/avacta-announces-first-patient-dosed-in-fifth-cohort-of-ava6000-phase-ia-dose-escalation-study\/","og_locale":"en_US","og_type":"article","og_title":"Avacta Announces First Patient Dosed in Fifth Cohort of AVA6000 Phase Ia Dose Escalation Study - Pharma Trend","og_description":"LONDON &amp; WETHERBY, England&#8211;(BUSINESS WIRE)&#8211;Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, announces that the first patient has been dosed in the fifth cohort of the first-in-human phase I trial (ALS-6000-101) of AVA6000. This follows the approval of an amended clinical trial protocol by the Medical ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/avacta-announces-first-patient-dosed-in-fifth-cohort-of-ava6000-phase-ia-dose-escalation-study\/","og_site_name":"Pharma Trend","article_published_time":"2023-04-05T08:03:29+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230405005422\/en\/1756840\/21\/Avacta_%28RGB%29_reg.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/avacta-announces-first-patient-dosed-in-fifth-cohort-of-ava6000-phase-ia-dose-escalation-study\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/avacta-announces-first-patient-dosed-in-fifth-cohort-of-ava6000-phase-ia-dose-escalation-study\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Avacta Announces First Patient Dosed in Fifth Cohort of AVA6000 Phase Ia Dose Escalation Study","datePublished":"2023-04-05T08:03:29+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/avacta-announces-first-patient-dosed-in-fifth-cohort-of-ava6000-phase-ia-dose-escalation-study\/"},"wordCount":324,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/avacta-announces-first-patient-dosed-in-fifth-cohort-of-ava6000-phase-ia-dose-escalation-study\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230405005422\/en\/1756840\/21\/Avacta_%28RGB%29_reg.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/avacta-announces-first-patient-dosed-in-fifth-cohort-of-ava6000-phase-ia-dose-escalation-study\/","url":"https:\/\/pharma-trend.com\/en\/avacta-announces-first-patient-dosed-in-fifth-cohort-of-ava6000-phase-ia-dose-escalation-study\/","name":"Avacta Announces First Patient Dosed in Fifth Cohort of AVA6000 Phase Ia Dose Escalation Study - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/avacta-announces-first-patient-dosed-in-fifth-cohort-of-ava6000-phase-ia-dose-escalation-study\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/avacta-announces-first-patient-dosed-in-fifth-cohort-of-ava6000-phase-ia-dose-escalation-study\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230405005422\/en\/1756840\/21\/Avacta_%28RGB%29_reg.jpg","datePublished":"2023-04-05T08:03:29+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/avacta-announces-first-patient-dosed-in-fifth-cohort-of-ava6000-phase-ia-dose-escalation-study\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/avacta-announces-first-patient-dosed-in-fifth-cohort-of-ava6000-phase-ia-dose-escalation-study\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/avacta-announces-first-patient-dosed-in-fifth-cohort-of-ava6000-phase-ia-dose-escalation-study\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230405005422\/en\/1756840\/21\/Avacta_%28RGB%29_reg.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230405005422\/en\/1756840\/21\/Avacta_%28RGB%29_reg.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/avacta-announces-first-patient-dosed-in-fifth-cohort-of-ava6000-phase-ia-dose-escalation-study\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Avacta Announces First Patient Dosed in Fifth Cohort of AVA6000 Phase Ia Dose Escalation Study"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55526","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=55526"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55526\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=55526"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=55526"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=55526"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}